ストックスクリーナーアプリを入手
7.5996
13.16%
0.8696
前日終値:
$6.73
開ける：
$6.69
24時間の取引高:
2.37M
Relative Volume:
0.92
時価総額：
$750.26M
収益：
-
当期純損益:
$-44.84M
株価収益率:
-16.17
EPS:
-0.47
ネットキャッシュフロー:
$-44.23M
1週間 パフォーマンス:
-7.24%
1か月 パフォーマンス:
-23.07%
6か月 パフォーマンス:
-46.44%
1年 パフォーマンス:
-43.08%
1日の値動き範囲:
$6.66
$7.68
1週間の範囲:
$6.66
$8.16
52週間の値動き範囲:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
名前
Ars Pharmaceuticals Inc
セクター
電話
858-771-9307
住所
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
SPRY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
7.59 | 665.25M | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.06 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
760.89 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
437.57 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.65 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
200.09 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-04 | 再開されました | Roth Capital | Buy |
| 2025-09-04 | 開始されました | Roth Capital | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-10 | 開始されました | Oppenheimer | Outperform |
| 2024-08-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 繰り返されました | Leerink Partners | Outperform |
| 2024-07-25 | 開始されました | Raymond James | Outperform |
| 2024-03-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | 開始されました | William Blair | Outperform |
| 2022-12-13 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
Is ARS Pharmaceuticals Inc. stock supported by strong fundamentals2025 Key Highlights & Precise Buy Zone Tips - newser.com
Will ARS Pharmaceuticals Inc. stock maintain momentum in 2025Earnings Overview Summary & Consistent Growth Stock Picks - newser.com
How ARS Pharmaceuticals Inc. stock benefits from strong dollarPortfolio Return Summary & Precise Entry and Exit Recommendations - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelineQuarterly Growth Report & AI Powered Market Entry Ideas - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery play2025 Market Trends & Accurate Buy Signal Alerts - newser.com
Can ARS Pharmaceuticals Inc. hit a new high this monthJuly 2025 Summary & Fast Momentum Entry Tips - newser.com
ARS Pharmaceuticals Inc. stock outlook for YEARQuarterly Growth Report & High Accuracy Buy Signal Tips - newser.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by ARS Investment Partners LLC - MarketBeat
Custom strategy builders for tracking ARS Pharmaceuticals Inc.Gold Moves & AI Enhanced Trading Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock is recommended by analysts2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
ARS Pharmaceuticals Insider Sold Shares Worth $1,476,147, According to a Recent SEC Filing - MarketScreener
Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks - Yahoo Finance
Applying chart zones and confluence areas to ARS Pharmaceuticals Inc.Quarterly Portfolio Report & Weekly Setup with ROI Potential - newser.com
Why ARS Pharmaceuticals Inc. stock could outperform in 2025Dollar Strength & Risk Managed Investment Strategies - newser.com
Why ARS Pharmaceuticals Inc. stock could see breakout soonPortfolio Gains Report & Risk Controlled Stock Pick Alerts - newser.com
ARS Pharmaceuticals targets renewed growth in 2026 as neffy adoption accelerates and new global launches begin - MSN
Multi factor analysis applied to ARS Pharmaceuticals Inc.2025 Trading Volume Trends & Safe Entry Momentum Stock Tips - newser.com
Will ARS Pharmaceuticals Inc. rebound enough to break evenJuly 2025 WrapUp & Reliable Entry Point Trade Alerts - newser.com
Why ARS Pharmaceuticals Inc. stock could rally in 2025Portfolio Risk Report & AI Driven Stock Movement Reports - newser.com
Dorsey, ARS Pharma COO, sells $190k in SPRY stock By Investing.com - Investing.com Canada
Insider Sell Alert: Brian Dorsey Sells 21,828 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus
ARS Pharma CBO Chakma sells shares worth $1.47 million By Investing.com - Investing.com Canada
Dorsey, ARS Pharma COO, sells $190k in SPRY stock - Investing.com
Reversal indicators forming on ARS Pharmaceuticals Inc. stockJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
Ars Pharmaceuticals Inc (SPRY) 財務データ
収益
当期純利益
現金流量
EPS
Ars Pharmaceuticals Inc (SPRY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Dorsey Brian | Chief Operating Officer |
Nov 13 '25 |
Sale |
8.71 |
21,828 |
190,050 |
10,789 |
| Chakma Justin | Chief Business Officer |
Nov 12 '25 |
Option Exercise |
0.84 |
30,000 |
25,200 |
166,380 |
| Chakma Justin | Chief Business Officer |
Nov 12 '25 |
Sale |
8.87 |
166,380 |
1,476,147 |
0 |
1.64%
0.70%
大文字化:
|
ボリューム (24 時間):